-
公开(公告)号：US20210170018A1
公开(公告)日：2021-06-10
申请号：US17122627
申请日：2020-12-15
发明人： Michael Houghton , Abdolamir Landi , Carlos A. Guzman , Thomas Ebensen , Darren Hockman , John L. Law , Michael Logan
IPC分类号： A61K39/29 , C07K14/18 , C07K14/33 , C12N15/86 , C01F11/02 , C07D323/00 , C07K14/34 , A61K39/39 , A61P31/14 , A61K39/12 , A61P37/04 , C07K14/28 , C07K14/005 , A61K39/00
摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.
-
2.发明授权公开(公告)号：US10408844B2
公开(公告)日：2019-09-10
申请号：US15543943
申请日：2016-01-26
IPC分类号： G01N33/68 , G01N33/563 , G01N33/58 , G01N33/74 , G01N33/96 , A61K38/18 , A61K38/19 , A61K38/20
摘要： The present disclosure provides methods and compositions that find use in facilitating a diagnosis of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in a subject. The methods and compositions involve measurement of at least one of proteins: IL-16, IL-7, VEGF, CXCL9, CX3CL1, CCL24, CCL19, and CCL11 in a body fluid sample of a subject suspected of having CFS/ME. Levels of one or more of the aforementioned proteins can be used to facilitate a diagnosis of a CFS/ME and/or confirm a diagnosis of CFS/ME. The methods and compositions of the present disclosure also find use in screening subjects for clinical trials and facilitating treatment decisions for a subject.
-
公开(公告)号：US20190224308A1
公开(公告)日：2019-07-25
申请号：US16374403
申请日：2019-04-03
IPC分类号： A61K39/29 , C12N15/861 , A61P31/14 , A61P37/04 , A61K39/12 , A61K39/295 , A61P31/04
摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.
-
公开(公告)号：US11324818B2
公开(公告)日：2022-05-10
申请号：US16334683
申请日：2017-09-21
发明人： Michael Houghton , Abdolamir Landi , Michael Logan , John L. Law , Darren Hockman , Chao Chen
摘要： The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.
-
公开(公告)号：US20220105175A1
公开(公告)日：2022-04-07
申请号：US17511177
申请日：2021-10-26
发明人： Michael Houghton , Abdolamir Landi , Michael Logan , John L. Law , Darren Hockman , Chao Chen
摘要： The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.
-
公开(公告)号：US10881727B2
公开(公告)日：2021-01-05
申请号：US16374403
申请日：2019-04-03
IPC分类号： A61K39/00 , C07K16/28 , A61K39/21 , A61K48/00 , C12N15/86 , A61K39/29 , A61K39/12 , A61P37/04 , A61P31/14 , A61P31/04 , A61K39/295 , C12N15/861
摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.
-
公开(公告)号：US20180169219A1
公开(公告)日：2018-06-21
申请号：US15574427
申请日：2016-07-06
IPC分类号： A61K39/29 , A61K39/295 , C12N15/861 , A61P31/14 , A61P31/04 , A61P37/04
CPC分类号： A61K39/29 , A61K39/12 , A61K39/295 , A61K2039/55544 , A61P31/04 , A61P31/14 , A61P37/04 , C07K2319/00 , C12N15/861 , C12N2770/24234
摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.
-
公开(公告)号：US20240252623A1
公开(公告)日：2024-08-01
申请号：US18529858
申请日：2023-12-05
发明人： Michael Houghton , John L. Law , Abdolamir Landi
IPC分类号： A61K39/29 , A61K39/00 , C07K14/005
CPC分类号： A61K39/29 , C07K14/005 , A61K2039/53 , A61K2039/70 , C12N2770/24222 , C12N2770/24234
摘要： The present disclosure provides nucleic acids comprising nucleotide sequences encoding hepatitis C virus (HCV) E1 and/or E2 polypeptides and/or one or more T-cell epitope polypeptides. The nucleic acids can comprise one or more modifications. The nucleic acids can be self-amplifying. The present disclosure provides compositions comprising the nucleic acids. The present disclosure provides methods of inducing an immune response to HCV in an individual, comprising administering to the individual a composition of the present disclosure.
-
公开(公告)号：US20240058438A1
公开(公告)日：2024-02-22
申请号：US18099035
申请日：2023-01-19
发明人： Michael Houghton , Abdolamir Landi , Carlos A. Guzman , Thomas Ebensen , Darren Hockman , John L. Law , Michael Logan
IPC分类号： A61K39/29 , A61P31/14 , A61P37/04 , A61K39/12 , C07K14/005 , A61K39/39 , C01F11/02 , C07D323/00 , C07K14/18 , C07K14/28 , C07K14/33 , C07K14/34 , C12N15/86
CPC分类号： A61K39/29 , A61P31/14 , A61P37/04 , A61K39/12 , C07K14/005 , A61K39/39 , C01F11/02 , C07D323/00 , C07K14/18 , C07K14/28 , C07K14/33 , C07K14/34 , C12N15/86 , A61K2039/543
摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.
-
公开(公告)号：US20230310590A1
公开(公告)日：2023-10-05
申请号：US18099044
申请日：2023-01-19
IPC分类号： A61K39/29 , A61K39/12 , A61P37/04 , A61P31/14 , A61P31/04 , A61K39/295 , C12N15/861
CPC分类号： A61K39/29 , A61K39/12 , A61P37/04 , A61P31/14 , A61P31/04 , A61K39/295 , C12N15/861 , C07K2319/00 , C12N2770/24234 , A61K2039/55544
摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.024 秒)
